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Abstract  74 
Objectives 75 
Stereotactic Ablative Radiotherapy (SABR) is a well-established treatment for medically 76 
inoperable peripheral stage I non-small cell lung cancer (NSCLC). Previous non-randomised 77 
evidence supports SABR as an alternative to surgery, but high quality randomised controlled 78 
trial (RCT) evidence is lacking. The SABRTooth study aimed to establish whether a UK 79 
phase III RCT was feasible. 80 
Design and Methods 81 
SABRTooth was a UK multi-centre, randomised controlled feasibility study targeting patients 82 
with peripheral stage I NSCLC considered to be at higher-risk of surgical complications. 83 
Fifty-four patients were planned to be randomised 1:1 to SABR or surgery. The primary 84 
outcome was monthly average recruitment rates.  85 
Results 86 
Between July 2015 and January 2017, 318 patients were considered for the study and 87 
205(64.5%) were deemed ineligible. Of 106 assessed as eligible (33.3%), 24 patients 88 
(22.6%) were randomised to SABR (n=14) or surgery (n=10). A key theme for non-89 
participation was treatment preference with 43 (41%) preferring non-surgical treatment and 90 
19(18%) preferring surgery.  The average monthly recruitment rate was 1.7 patients against 91 
a target of 3. Fifteen patients underwent their allocated treatment, 12 SABR, 3 surgery.  92 
Conclusions 93 
We conclude that a phase III RCT randomising higher-risk patients between SABR and 94 
surgery is not feasible in the National Health Service (NHS). Patients have pre-existing 95 
treatment preferences, which was a barrier to recruitment. A significant proportion of patients 96 
randomised to the surgical group declined and chose SABR. SABR remains an alternative to 97 
surgery and novel study approaches are needed to define which patients benefit from a non-98 
surgical approach. 99 
 100 
 101 




Stage I non-small cell lung cancer (NSCLC) is curable, with surgery considered the standard 104 
of care for medically fit patients. Reported 5-year overall survival (OS) rates range from 53-105 
89% for stage IA1-3 disease and 49-71% for stage IB disease (1). However, a significant 106 
proportion of patients with Stage I NSCLC are not suitable for surgery because of their age 107 
and/or poor fitness, often related to a patient’s significant medical co-morbidities. This is 108 
confirmed in the UK with data from the most recently published National Lung Cancer Audit 109 
(NLCA) where only 60.6% of stage I-II patients with a performance status of 0-2 underwent 110 
surgery (2). This confirms that a significant proportion of patients are deemed to be at higher 111 
risk of surgical complications including death.  112 
An alternative approach to treating these ‘higher risk’ is stereotactic ablative radiotherapy 113 
(SABR). For medically inoperable peripherally located stage I NSCLC, SABR has been 114 
shown to have improved overall survival rates and better local control (3) and better quality 115 
of life (4) when compared with conventional fractionated radical radiotherapy. Propensity 116 
matched retrospective series of SABR in operable patients suggest that SABR may be an 117 
alternative to surgery whilst others have favored surgery (5-8).  A systematic review of 118 
studies published between 2006 and 2013 showed an equivalent 2-year OS between SABR 119 
and surgery (9) and similarly, a meta-analysis of articles published between 2000 and 2012 120 
indicated no significant difference in OS between the two treatment strategies (10). Finally, a 121 
single-centre competing risk analysis has shown no difference in cancer-specific survival 122 
between SABR and surgery in unmatched patients (11)  123 
However, all these analyses are limited due to the quality of the retrospective data and, even 124 
with propensity matching; case selection and other significant factors (e.g. specific co-125 
morbidity, smoking history, and socio-economic factors) cannot be accounted for fully. 126 
Randomised trials for medically operable patients have been attempted in the past and 127 
closed prematurely due to failure to recruit (ROSEL (NCT00687986), STARS 128 
(NCT00840749), and ACOSOG-RTOG (NCT01336894) (12-14). A pooled analysis of the 129 
STARS and ROSEL trials suggested that SABR was better tolerated and may lead to better 130 
OS than surgery for operable stage I NSCLC. This pooled analysis provoked significant 131 
debate in the lung cancer community and the consensus was that a larger RCT was required 132 
to validate these results (13). Researchers involved in the ACOSOG – RTOG trial 133 
recommended that such a study would require commitment by investigators when 134 
discussing the trial with patients and close collaboration between surgeons and radiation 135 
oncologists (14). Ultimately, clinician and patient acceptability of a challenging randomisation 136 
between SABR and surgery is key to the successful conduct of such trial. 137 
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The main challenge when trying to compare two very different treatment modalities with 138 
differing toxicity and treatment-related mortality profiles is to achieve equipoise amongst 139 
clinicians and patients. The aim of the SABRTooth study was to determine the feasibility and 140 
acceptability of conducting a large definitive phase III RCT comparing surgery with SABR in 141 
patients with Stage I NSCLC deemed to be at a higher risk of surgical complications.  142 
 143 
Material and Methods 144 
Study design and participants 145 
The SABRTooth study was a UK-based, multi-centre, open-label, parallel-group randomised 146 
controlled feasibility study in patients with peripheral stage I NSCLC considered to be at 147 
higher risk of complications from surgical resection.  148 
In total, 54 patients were planned to be recruited to provide evidence that when recruitment 149 
rates were scaled up, a large-definitive phase III RCT would be possible. Recruitment was 150 
from four established thoracic surgical centres and one selected larger referral unit.  151 
Ethical approval was granted by Yorkshire and The Humber – Leeds West Research Ethics 152 
Committee (ref: 14/YH/1162). All patients provided written informed consent.  153 
Full details of the study protocol have been published previously (15). Patients were 154 
identified by lung cancer teams through the multi-disciplinary team (MDT) meetings, after 155 
assessment of eligibility. The core eligibility criteria did not change during the study (Table 156 
1). Guidance for defining patients at a higher-risk from surgical complications from a 157 
lobectomy was based on national and international standard criteria  (e.g. lung function, 158 
performance status, fitness assessment), Thoracoscore and the “Nottingham” nomogram 159 
(Table 2) (16). Pre-treatment investigations were as reported previously (15). All data/scores 160 
were recorded prospectively but ultimately, the final decision on patient eligibility rested with 161 
the local MDT.  162 
Randomisation and masking 163 
Patients were randomised (1:1) to surgery or SABR using a 24-hour telephone or web-based 164 
system centrally governed by the Clinical Trials Research Unit, University of Leeds (15).  165 
Procedures  166 
Treatment was aimed to start within 31 days of randomisation, in line with NHS guidelines. 167 
The aim of surgery was a R0 resection; both thoracotomy and Video Assisted Thoracoscopic 168 
Surgery (VATS) were acceptable. The recommended procedure was an anatomical resection, 169 
ideally by lobectomy or an anatomical segmentectomy if not suitable for lobectomy. Sub-lobar 170 
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or wedge resection was acceptable if an anatomical resection was not deemed possible by the 171 
treating surgeon. Sampling of at least three lobe-specific N2 nodal stations was 172 
recommended, though for wedge resections lymph node sampling was not mandated, as, due 173 
to patient factors, the duration of the anaesthetic may need to be minimised. Post-operative 174 
care was as per local unit protocols. Participants who were assessed as being unfit for surgery 175 
pre-operatively were treated according to local guidelines.  176 
SABR treatment was based on the accepted guidelines of the UK SABR consortium (17) for 177 
peripherally located stage I NSCLC, with three dose schedules based on the location of the 178 
tumour (supplementary material). Where participants were unable to receive their allocated 179 
treatment, e.g. if a SABR plan didn’t meet planning objectives, radical radiotherapy or 180 
surgery would be considered according to local guidelines. Radiotherapy quality assurance 181 
was provided by the NCRI Radiotherapy Trials Quality Assurance Team (RTTQA). Details of 182 
the trial radiotherapy quality assurance are contained in the supplementary material: 183 
SABRTooth Radiotherapy Guidelines. 184 
Treatment related complications were treated as per local guidelines.  185 
Data collection 186 
All patients considered for the study were ‘tracked’ up until the point of randomisation to 187 
establish reasons for drop-out. Follow-up frequency and data collection was as previously 188 
reported (15) and in line with current NHS practice.  189 
Complications, defined as any untoward medical event that has a causal relationship to the 190 
study or administration of any procedures, were collected from the end of surgery or final 191 
SABR administration until the end of the follow-up period. Serious complications (SCs) and 192 
unexpected serious complications (USCs) required reporting within 30 days of surgery or final 193 
SABR administration. 194 
A qualitative sub-study explored in up to 15 patients, their acceptability of the study. Eligible 195 
patients who declined study participation, or participants who were randomised but did not 196 
take up their treatment allocation were invited to take part in a feedback interview to identify 197 
reasons for their choices.  198 
Intended recruitment pathways were captured via site-specific visits prior to the start of 199 
recruitment. A follow-up questionnaire captured changes to intended recruitment pathways, 200 
tools/criteria used to identify eligible patients and factors perceived to be a driver or challenge 201 
to recruitment.   202 
Outcomes 203 
The primary objective of the study was to quantitatively assess recruitment rates i.e. patients 204 
providing consent for randomisation into the study, regardless of uptake of their randomised 205 
treatment procedure. An average rate of three patients per month across the five centres 206 
was needed over a formal monitoring period to demonstrate that a phase III trial would be 207 
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feasible in the UK. The formal monitoring of recruitment period began 6 months after the 208 
start of recruitment (allowing for a run-in period for site set-up) for 13 months. Table 3 details 209 
the secondary and exploratory objectives. 210 
Recruitment strategies 211 
Significant efforts were made during study development to optimise recruitment.  During the 212 
study, aspects of the recruitment strategy were modified based on feedback received from 213 
sites and patients. Aspects of these approaches are detailed in Table 4.  214 
Statistical analysis 215 
The final analysis took place after the final participant had been followed up for 6 months. 216 
Analyses involved descriptive and summary statistics and no formal hypothesis testing was 217 
conducted. The primary endpoint analysis was based on the population of patients recruited 218 
during the formal monitoring period. The treatment and safety data are presented for the 219 
safety population, i.e. participants who received at least one dose of radiotherapy or who 220 
underwent surgery. The screening data is presented for the screening population, i.e.  221 
patients who were screened for entry into the study All further analyses were carried out 222 
using the intention-to-treat (ITT) population.    223 
All analyses were performed in SAS version 9.4.  224 
A Trial Steering Committee (TSC) met to review the safety and ethics of the study prior to 225 
opening to and during recruitment.  226 
 227 
Results 228 
Between 1 July 2015 and 31 January 2017, 318 patients were considered for the study. 106 229 
(33.3%) were initially assessed as eligible and 84 (79.2%) were approached to take part. In 230 
total, 24 patients were randomised (28.6%), 14 to SABR and ten to surgery from five UK 231 
centres (Figure 1). The last date of patient follow-up was in July 2017. 232 
Figure 2 presents the flow of patients through the screening process and reason for patients 233 
not assessed as eligible, not approached or declining randomisation where known. The trial 234 
population was representative of the general lung population with stage I NSCLC. Of the 84 235 
patients initially assessed as eligible and approached for the study, 52 (61.9%) declined 236 
randomisation with 42.3% (n=22) preferring SABR and 28.8% (n=15) for surgery; eight 237 
patients did not want surgery, six did not wish to enter a trial and one patient did not specify 238 
a reason. 239 
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Table 5 presents the baseline demographic and disease related characteristics of the 240 
randomised study population. The median age was 75 years (54-88) and the majority were 241 
female (n=14, 58.3%). All but one participant presented with one or more pre-existing 242 
condition. Surgical participants had a larger median tumour size (2.7 vs 1.9cm) and greater 243 
proportion of stage T2a tumours (70.0% vs 21.4%) compared to SABR.  244 
Twenty-four patients were randomised over the whole recruitment period (14 SABR, 10 245 
Surgery).  With a median recruitment rate of 4 patients across the 5 recruiting centres 246 
(range: 1, 9). The formal assessment of the primary endpoint began 6 months after the start 247 
of recruitment and over the 13-month formal monitoring of recruitment period, 22 patients 248 
were randomised (12 SABR, 10 Surgery). There was an average recruitment rate of 1.7 249 
patients per month falling short of the required three patients per month to meet the primary 250 
endpoint and demonstrate feasibility of recruitment. All five recruiting sites recruited to the 251 
study. 252 
Of the 24 participants randomised, 62.5% (n=15) underwent their allocated treatment 253 
procedure; 30.0% (n=3) of participants randomised to surgery compared to 85.7% (n=12) 254 
randomised to SABR (Figure 1). Of the seven participants not undergoing surgery, all were 255 
tumour stage T2a. Five did not wish to have surgery and two were deemed to be ineligible 256 
post-randomisation (Figure 1). All seven participants went on to receive radiotherapy (six 257 
SABR, one conventionally fractionated radiotherapy). In the SABR group, one participant 258 
was deemed ineligible post-randomisation and received radical radiotherapy; the final 259 
participant was lost to follow-up.  260 
Median time from randomisation to start of treatment for the 3 surgery and 12 SABR 261 
participants was 38 days (range: 20 to 61) and 29 days (range: 19 to 48) respectively. All 262 
participants who underwent protocol treatment received it as planned. The surgical 263 
procedure undertaken was either VATs (n=2) or open (n=1). SABR dose fractionation was 264 
as per the UK SABR Consortium guidelines with 3 participants receiving 54 Gy in 3 fractions, 265 
8 receiving 55Gy in 5 fractions, and 1 receiving 60Gy in 5 fractions.  Median time between 266 
surgical operation date and date of discharge was 13 days (range: 4 to 15). Median time on 267 
study measured from randomisation to date of last follow-up, withdrawal or death was 9.2 268 
months (range: 0.2 to 20.3), 11.8 months (range: 4.1 to 20.3) for SABR and 7.6 months 269 
(range: 0.2 to 12.7) for surgery.   270 
Table 6 presents the compliance rates with the EQ-5D-5L and EQ-VAS questionnaires. 271 
Compliance rates for the QLQ-C30, QLQ-LC13 and Use of Resources questionnaires were 272 
similar and for returned questionnaires, the completion rates were high. The mean and 273 
standard deviation of the EQ-5D utility scores (where scores could be derived) for surgery 274 
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and SABR respectively were 0.8(0.22) (n=10) and 0.8(0.09) (n=14) at baseline; 0.9(0.14) 275 
(n=5) and 0.8(0.11) (n=13) pre-treatment; 0.7(0.35) (n=7) and 0.8(0.11) (n=13) at 6 weeks; 276 
0.7(0.34) (n=6) and 0.7(0.20) (n=12) at 3 months; 0.7(0.45) (n=4) and 0.7(0.17) (n=10) at 6 277 
months. Beyond this, data are limited in the surgical group. Summaries of the QLQ-C30, 278 
QLQ-LC13 and Use of Resources questionnaires are available on request.  279 
In the surgical group, 23.8% (5/21) of all the reported complications were CTCAE grade 3 280 
compared to 8.7% (6/69) of events in the SABR group. All complications were attributed to 281 
protocol treatment and were expected.  282 
At the time of final analysis there were three participant deaths. One occurred four days 283 
post-surgery due to a post-operative bronchopneumonia in a patient with ischaemic heart 284 
disease. Two participants in the SABR group died 326 and 405-days post-treatment due to 285 
progressive lung cancer and unrelated septicaemia. 286 
Qualitative Research 287 
Twelve patients took part in the qualitative interviews, nine who had declined participation 288 
and three who declined to take up their randomised allocation to surgery. These patients had 289 
a clear preference for surgery or SABR. Further details are provided in the supplementary 290 
material, but key themes included: 1) the complexity of decision making when choosing 291 
between different treatments alongside the decision to take part in a trial; 2) patients making 292 
sense of their decision by talking to health care professionals, family and friends, or using 293 
their own prior experience or knowledge of the treatment.   294 
Recruitment pathways were similar between sites as presented in the supplementary 295 
material. However, strategies for introducing and discussing the study with patients were 296 
adapted in each centre. Mentioning the study earlier in the patient pathway was found to be 297 
helpful and did not overburden patients with information. Table 7 presents a summary of the 298 
perceived challenges to recruitment, and factors believed to encourage recruitment from a 299 
site perspective.  300 
The assessment criteria and tools used to identify suitable study patients varied between 301 
sites. MDT opinion and ECOG performance status were always used.  302 
 303 
Discussion 304 
The SABRTooth feasibility study failed to achieve the predefined recruitment target of an 305 
average of three patients per month during the 13-month formal monitoring period; 306 
demonstrating that a larger phase III RCT of SABR versus surgery is not possible in the UK. 307 
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Despite the lower than anticipated recruitment, a great deal of insight was obtained about 308 
running a trial in this context in the UK.  309 
Multiple secondary endpoints were studied to evaluate the most optimal study design and 310 
explore reasons for participation/non-participation. Adaptation and learning were built into 311 
the trial, employing strategies that had been successful in other randomised trials between 312 
surgery and  non-surgical treatments (18).  The recruitment strategy was modified 313 
throughout the study based on feedback from sites and through greater understanding the 314 
complexity of the conversations between patients and clinicians when discussing this trial.  315 
Alternative approaches to randomisation were also considered including the pre-316 
randomisation model employed in the STABLE-MATES trial (NCT02468024). It was felt that 317 
there was insufficient evidence, and concerns around the methodological robustness of this 318 
design to support this change during the recruitment period of SABRTooth (19).   319 
The reasons for the SABRTooth study failing to recruit are complex and reflect both pre-320 
existing patient and clinician preferences as detailed in Table 7. 321 
Consenting and randomising patients prior to meeting the treating surgeon or oncologist by a 322 
research lung research nurse and/or respiratory physician was intended to remove treating 323 
clinician bias but may also have contributed to the high surgical dropout. Education and 324 
training were provided before and during the SABRTooth study to the research nurses and 325 
respiratory physicians to try and optimise the explanation of the trial and facilitate consent. 326 
Given the relatively small numbers of researchers and patients it was not possible to assess 327 
if clinician bias consciously or subconsciously influenced the patients and hampered 328 
patient’s acceptance of randomisation. However, it is important to note that approximately 329 
70% of the patients who were considered eligible but declined the study had a preference for 330 
non-surgical treatments and were predominantly older with significant comorbidities.  331 
Targeting “higher-risk” patients reduced the number of potential eligible patients but reflected 332 
patients for where there is most clinician equipoise between surgery or SABR. Approached 333 
patients found the study information to be clear and well-presented which often prompted   334 
more in-depth conversation with clinicians regarding their treatment options. Therefore, all 335 
approached patients would have been aware they were higher risk for surgery and been 336 
more aware of all the treatment options, particularly the option of a non-surgical approach. 337 
This may have influenced the patient’s equipoise as patients had a clear preference for one 338 
of the treatment options when asked. Patients were clear that this was personal decision 339 
which they wanted to make for themselves, often after talking to health professionals, family 340 
or friends.  341 
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In an era of increasing availability of information of treatment options, through formal 342 
literature, on-line information and patient forums, patients are, and will continue to be better 343 
informed of their treatment options. The SABRTooth study has shown that the majority of 344 
eligible patients, when given further information on both options, have a treatment 345 
preference for a non-surgical approach, both in the screened population and for those 346 
patients randomised to surgery. 347 
We need to involve patients in the treatment decision-making process and a shared decision 348 
making (SDM) approach is of growing interest in oncology studies. This is particularly 349 
relevant when the treatment options are preference sensitive i.e. when there are multiple 350 
suitable treatment options. It is however recognised that incorporating SDM into daily clinical 351 
practice brings its own challenges (20) and requires skilled clinicians, a combination of 352 
interventions that support the patient, clinician and organisation and “buy-in” from the clinical 353 
team and organisation (21).  354 
SABRTooth has shown that is it not feasible to randomise higher-risk stage I non-small cell 355 
lung cancer patients to surgery or SABR in the NHS. However, there are ongoing RCTs in 356 
similar populations (at the time of publication) which include the VALOR (NCT02984761 and 357 
STABLE-MATES (NCT02468024) studies which are open to recruitment in North America 358 
and may answer this important research question.  359 
Further work is required to address the issues raised in the SABRTooth study. Whilst a 360 
randomised trial might be feasible where there are sufficient resources to address the 361 
equipoise of all involved, the extent to which this could be applied in routine clinical practice 362 
would be limited. Thus, randomising between SABR and surgery is challenging within the 363 
NHS, particularly when focusing on a well-informed selected older population with 364 
comorbidities. Despite RCTs being considered a gold standard framework for evaluating 365 
clinical trials, they are not always suitable to answer every question. Alternative strategies are 366 
needed to provide the evidence to assist policy makers, practitioners and patients to decide 367 
the most appropriate treatment. Future studies for high-risk patients with stage I/II NSCLC 368 
may benefit from non-randomised designs that take account of the decision making and 369 
preferences of the patients and clinicians as part of shared decision making. 370 
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Analysis populations: 
Intention-to-treat population (n=10): 
Safety population (n=3): 
- Excluded as did not receive surgery (n=7) 
Analysis populations: 
Intention-to-treat population (n=14): 
Safety population (n=12): 
- Excluded as did not receive SABR (n=2) 
 
*We are still to receive further details for 1 participant 
undergoing further investigations 
 
Excluded (n=294) 
- Patient not assessed for eligibility (n=7)  
- Patient clinically ineligible (n=205)  
- Patient not approached (n=22)  
- Patient not randomised (n=60) 
 Subsequently found to be 
ineligible (n=8) 
 Patient declined (n=52) 
Withdrawn consent from any aspect of trial 
(n=6): 
- From trial treatment only (n=5) 
- From trial treatment and questionnaire 
completion only (n=0) 
- From trial treatment and data collection at 
standard visits only (n=0) 
- From all aspects of the trial (n=1) 
Post-randomisation ineligibility (n=2):  
 Deemed unfit for surgery* 
 Suprasternal positive node found at 
mediastinoscopy 
*Clinician decision. Participant also submitted a 




Allocated to Surgery (n=10): 
- Received surgery (n=3) 
- Did not receive surgery (n=7)  
 
Withdrawn consent from any aspect of trial 
(n=0): 
 
Post-randomisation ineligibility (n=1) 
 Tumour close to pericardium 
 
Lost to follow up prior to treatment (n=1) 
 
 
Allocated to SABR (n=14): 
- Received SABR (n=12) 








































Patients considered for the 
study (n=318) 
Initially assessed as eligible 
(n=106) 
Approached to take part in the 
study (n=84) 
Not approached for the study (n=22) 
- Patient preference for SABR (n=6, 27.3%) 
- Patient preference for surgery (n=4, 18.2%) 
- MDT preference for surgery (n=2, 9.1%) 
- Patient did not want surgery (n=7, 31.8%) 
- Patient did not wish to take part in the trial (n=1, 4.5%) 
- Other (n=2, 9.1%) 
Agreed to be randomised 
(n=24) 
Subsequently found to be ineligible (n=8) 
Declined randomisation (n=52) 
- Patient preference for SABR (n=22, 42.3%) 
- Patient preference for surgery (n=15, 28.8%) 
- Patient did not want surgery (n=8, 15.4%) 
- Patient did not wish to take part in the trial (n=6, 11.5%) 
- No reason given (n=1, 1.9%) 
Not assessed (n=7) 
Not assessed as eligible (n=205) 
- Too high risk / not eligible for surgery (n=64, 31.2%) 
- Not high risk / fit for surgery (n=55, 26.8%) 
- Too central for SABR (n=10, 4.9%) 
- Active surveillance (n=10, 4.9%) 
- Best supportive care (n=8, 3.9%) 
- Not NSCLC (n=8, 3.9%) 
- Other (n=50, 24.4%%) 
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Table 1. Eligibility criteria 464 
Inclusion Criteria Exclusion Criteria 
1. Histological and/or clinical and radiological 
diagnosis of NSCLC 
2. Primary tumour characteristics: 
i. Peripherally located tumour as defined 
in the RTOG 0236 study and UK SABR 
Consortium guidelines. This states that 
the tumour must be more than 2cm in 
axial diameter from a major airway = 
“No Fly Zone”. This includes the 
trachea, carina, right and left main 
bronchus and extends to the bifurcation 
of the right upper, right middle, right 
lower, left upper and left lower lobe 
bronchioles 
ii. Maximal axial diameter of ≤ 5 cm 
measured on lung windows on 
computed tomography 
3. No evidence of hilar or mediastinal lymph 
nodes involvement. Any hilar or 
mediastinal lymph nodes that are either 
PET positive or >1cm in axial dimension 
must be sampled by mediastinoscopy, 
endo-bronchial ultrasound or oesophageal 
endoscopic ultrasound and demonstrate 
negative cytology and/or pathology 
4. Local lung cancer MDT consensus opinion 
that patient is considered suitable for either 
surgical resection or SABR treatment and 
to be at higher risk of complications from 
surgical resection 
5. Age ≥ 18 
6. Female patients must satisfy the 
investigator that they are either not of 
childbearing potential or not pregnant (i.e. 
1. Previous radiotherapy within the planned 
treatment volume 
2. History of clinically significant diffuse 
interstitial lung disease 
3. Any history of concurrent or previous 
invasive malignancy that, in the opinion of 
the investigator, could impact on trial 
outcomes 
4. Clinical or radiological evidence of 
metastatic spread 
5. History of psychiatric or addictive disorder 
or other medical condition that, in the 
opinion of the investigator, would 
preclude the patient from meeting the trial 
requirements 
6. Previous systemic therapies, including 
targeted and experimental treatments, for 




be willing to undergo a pregnancy test 
within 72hrs of surgery or day 1 of SABR 
treatment) 
7. Able and willing to provide written informed 
consent. 
 465 
Table 2: Definition of ‘higher risk’ for surgery 466 
We have suggested the below criteria for all groups to assist patient selection. However, 
as there are other individual contributing factors the final decision on whether the patient 
is suitable for the trial will rest with the local MDT 
Group A 
Suitable for 
Surgery - BUT at 







 CPEX – VO2 Max 10-15 L/kg/min  
 ISWT – walk 250-400 metres  
 Mortality Risk from Nottingham score -6-20% at 
90 days (Derived using the SABRTooth trial 
calculator provided) 
The patient can 
be approached 
for the trial if 
they meet one 






Lower risk of 
complications 
 CPEX- VO2 Max >15 L/kg/min, Anaerobic 
Threshold  
 ISWT – walk > 400 metres and without 
significant desaturation  
 Predicted post-operative FEV1 > 50%  
 Mortality Risk from Nottingham score <6% at 90 
days for lobectomy (Derived using the 
SABRTooth trial calculator provided). It is not 
anticipated that patients will need a 
pneumonectomy in this group of peripheral 
cancers. 
 






predicted risk of 
complications too 
high 
 CPEX- VO2 Max <10 L/kg/min  
 ISWT – walk < 250 metres and significant 
desaturation  
 Pre-operative FEV1 < 30%  
 Mortality Risk from Nottingham score > 20% at 
90 days for lobectomy (Derived using the 
SABRTooth trial calculator provided). It is not 




anticipated that patients will need a 
pneumonectomy in this group of peripheral 
cancers. 
 Reduced ejection fraction (e.g. < 40%) or 
evidence of ongoing myocardial ischaemia.  
 • Recent cerebro-vascular event (e.g. within 3 
months of planned surgery) 
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Table 3. Secondary and exploratory objectives 468 
Secondary objectives 
 To determine the number of patients screened and identified as eligible 
 To assess the uptake of allocated treatment procedure   
 To assess reasons for non-participation of eligible patients and participants not 
undergoing their allocated treatment procedure 
 To assess the feasibility of collecting QoL and Use of Resources data and determine the 
optimal frequency of data collection 
 To obtain EQ-5D utility estimates to inform the sample size calculations for a future phase 
III trial 
Exploratory objectives 
 To qualitatively explore in a cohort of patients their acceptability of the study 
 To explore participant recruitment pathways at both treatment centres and referral units 
 To explore the use of available tools in defining patients at a higher risk from surgical 
resection  












Table 4. Strategies to optimise recruitment 477 
During study development 
 Establishing an MDT group and conducting study workshops to develop the grant 
application and design the protocol. The MDT group comprised clinical oncologists, 
surgeons, chest physicians, patient and public representatives, statisticians and trial 
managers 
 Establishing recruitment pathways which reflected the well-established referral pathways 
for cancer patients in the NHS whereby all cancer patients’ cases are discussed in an MDT 
meeting before a treatment decision is made, allowing all suitable patients to be screened 
 Hosting a launch meeting to achieve and maximise ‘buy-in’ from the surgeons, respiratory 
physicians and oncologists from each participating site before the study opened. Patient 
representatives provided guidance on how to approach patients with “mock” consultations 
 Ensuring the study was introduced to patients, and suitable patients were consented, by 
the research nurse and/or respiratory physician before meeting a surgeon and/or 
oncologist to reduce any clinician bias when describing the equipoise between the two 
treatments 
During recruitment 
 Developing recruitment aids for the Research Nurses and Clinicians including: a one-page 
MDT summary sheet to aid identification of potential patients, a more detailed eligibility 
aide-memoir, a flip-chart to aid discussions of the treatments and randomisation process 
with patients and recruitment training videos of mock consultations 
 Developing recruitment aids for patients with the focus of describing the equipoise between 
the two treatments. Including a patient video describing the study and a shorter two-page 
participant information leaflet and publicity posters for clinic waiting areas 
 Conducting multiple study workshops/training days for the research nurses and patient and 
public representatives throughout the study and additional meetings/presentations at the 
British Thoracic Oncology Group annual conference (2016, 2017) 
 Site visits mid-way through the study by the Chief Investigator and Trial Manager to 
observe lung MDT meetings, meet local the local team and provide refresher training on 
study processes.  
 Regular email updates on study progress via newsletters 
 Hosting video-calls with sites to identify any challenges to recruitment and share ‘best 












Gender    
Female 6 (60.0%) 8 (57.1%) 14 (58.3%) 
Male  4 (40.0%) 6 (42.9%) 10 (41.7%) 
Age     
Mean (s.d.) 71.9 (6.06) 76.0 (11.46) 74.3 (9.63) 
Median (range) 73.5 (63.0, 79.0) 79.0 (54.0, 88.0) 75.0 (54.0, 88.0) 
Missing 0 0 0 
Pre-existing conditions    
Yes 9 (90.0%)  14 (100%)  23 (95.8%) 
No 1 (10.0%) 0 (0.0%) 1 (4.2%) 
Cancer type    
Adenocarcinoma 5 (83.3%) 6 (75.0%) 11 (78.6%) 
Squamous cell cancer 1 (16.7%) 1 (12.5%) 2 (14.3%) 
Unknown* 0 (0.0%) 1 (12.5%) 1 (7.1%) 
ECOG performance status   
0 4 (40.0%) 2 (14.3%) 6 (25.0%) 
1 4 (40.0%) 10 (71.4%) 14 (58.3%) 
2 2 (20.0%) 2 (14.3%) 4 (16.7%) 
Tumour stage    
T1a 1 (10.0%) 8 (57.1%) 9 (37.5%) 
T1b 2 (20.0%) 3 (21.4%) 5 (20.8%) 
T2a 7 (70.0%) 3 (21.4%) 10 (41.7%) 
Tumour size (cm)    
Mean (s.d.) 2.5 (0.84) 2.1 (0.78) 2.3 (0.82) 
Median (range) 2.7 (0.7, 3.5) 1.9 (1.2, 4.3) 2.2 (0.7, 4.3) 
Missing 0 0 0 
Charlson co-morbidity index 
Mean (s.d.) 3.7 (1.83) 3.9 (3.15) 3.8 (2.63) 
Median (range) 4.0 (1.0, 6.0) 3.5 (1.0, 13.0) 4.0 (1.0, 13.0) 
Missing 0 0 0 
Thoracoscore (%)    
Mean (s.d.) 3.2 (2.81) 3.0 (1.31) 3.1 (2.05) 









Missing 0 1 1 
Nottingham risk score (%) 
Mean (s.d.) 6.2 (3.58) 6.3 (2.82) 6.3 (3.08) 
Median (range) 6.8 (2.0, 10.9) 5.8 (2.7, 12.7) 6.0 (2.0, 12.7) 
Missing 0 0 0 
* Patient lost to follow-up before result confirmed  481 
 482 
Table 6. EQ-5D-5L and EQ-VAS compliance rates 483 
Questionnaires Received Surgery n (%) SABR n (%) Total n (%) 
Baseline questionnaire    
Yes 10 (100.0%) 14 (100.0%) 24 (100.0%) 
No 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Total 10 (100%) 14 (100%) 24 (100%) 
Pre-treatment questionnaire    
Yes 5 (50.0%) 13 (92.9%) 18 (75.0%) 
No 5 (50.0%) 1 (7.1%) 6 (25.0%) 
Total 10 (100%) 14 (100%) 24 (100%) 
6 week (clinic visit)    
Yes 6 (75.0%) 13 (92.9%) 19 (86.4%) 
No 2 (25.0%) 1 (7.1%) 3 (13.6%) 
Total 8 (100%) 14 (100%) 22 (100%) 
3 month (clinic visit)    
Yes 5 (62.5%) 12 (85.7%) 17 (77.3%) 
No 3 (37.5%) 2 (14.3%) 5 (22.7%) 
Total 8 (100%) 14 (100%) 22 (100%) 
6 month (clinic visit)    
Yes 3 (42.9%) 10 (83.3%) 13 (68.4%) 
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Questionnaires Received Surgery n (%) SABR n (%) Total n (%) 
No 4 (57.1%) 2 (16.7%) 6 (31.6%) 
Total 7 (100%) 12 (100%) 19 (100%) 
9 month (clinic visit)    
Yes 0 (0.0%) 8 (88.9%) 8 (50.0%) 
No 7 (100.0%) 1 (11.1%) 8 (50.0%) 
Total 7 (100%) 9 (100%) 16 (100%) 
12 month (clinic visit)    
Yes 1 (25.0%) 5 (83.3%) 6 (60.0%) 
No 3 (75.0%) 1 (16.7%) 4 (40.0%) 
Total 4 (100%) 6 (100%) 10 (100%) 
15 month (postal)    
Yes 0 (0.0%) 2 (66.7%) 2 (40.0%) 
No 2 (100.0%) 1 (33.3%) 3 (60.0%) 
Total 2 (100%) 3 (100%) 5 (100%) 
18 month (clinic visit)    
Yes n/a 1 (50.0%) 1 (50.0%) 
No n/a 1 (50.0%) 1 (50.0%) 
Total 0 2 (100%) 2 (100%) 
 484 
Footnote: The denominator represents the number of expected questionnaires at each time 485 
point, excluding those participants who had died, withdrawn from QoL or did not reach that 486 








Table 7. Site perceived drivers and challenges to recruitment 493 
Recruitment Drivers Recruitment Challenges 
Patient factors 
 patients not having a treatment preference 
Recruiter factors 
 introducing the study as early as possible 
 providing patients with appropriate level of 
information 
 equipoise and effectiveness of both 
treatments being clearly explained to the 
patients so they that felt comfortable with 
the concept of randomisation 
 the strategy for discussion of the study with 
the patient, including the terminology used 
e.g. ‘early stage lung cancer’ and ‘cure’ 
were seen as being important  
 follow-up calls to help patients consolidate 
their thinking about the study and address 
any concerns 
Site factors: 
 clear channels of communication between 
the teams at site 




 patients having a treatment preference  
o often influenced by their awareness of 
their illness and comorbidities, 
preconceived ideas about the 
risk/benefits of surgery/SABR, previous 
treatment experiences (be it themselves 
or friends/relatives) 
o patients did not like having the decision 
removed from them, and were not used 
to clinicians having uncertainty about 
the best treatment options 
Recruiter factors 
 patients being overloaded with information 
potentially making their decision harder 
 ethical issues around ‘challenging’ patient 
preferences and difficulties in challenging 
the MDTs opinions  
 lack of equipoise of research nurses/other 
team members which may be conveyed 
unconsciously to patients 
 difficulty in defining ‘higher-risk’ and 
patients towards to the lower end of the 
scale but still eligible often being sent 
towards surgery 
 pool of eligible patients not being as big as 
expected 
 resection rates published on a national 
audit which may lead to a push for surgery 
Site factors 
 clerical issues meaning patients were 
referred straight to surgery 
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 time pressures of MDT discussions to 
discuss and identify all potentially suitable 
patients 
 staffing levels and additional time 
pressures on staff to identify and discuss 
the study with patients which require longer 
appointments 
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